Similar articles

• Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice.

  Steffens S, Veillard NR, Arnaud C, Pelli G, Burger F, Staub C, Karsak M, Zimmer A, Frossard JL, Mach F. Steffens S, et al. Nature. 2005 Apr 7;434(7034):782-6. doi: 10.1038/nature03389. Nature. 2005. PMID: 15815632
• Macrophages eyed in macular degeneration.

  Forrester JV. Forrester JV. Nat Med. 2003 Nov;9(11):1350-1. doi: 10.1038/nm1103-1350. Nat Med. 2003. PMID: 14595424 No abstract available.
• Differential influence of chemokine receptors CCR2 and CXCR3 in development of atherosclerosis in vivo.

  Veillard NR, Steffens S, Pelli G, Lu B, Kwak BR, Gerard C, Charo IF, Mach F. Veillard NR, et al. Circulation. 2005 Aug 9;112(6):870-8. doi: 10.1161/CIRCULATIONAHA.104.520718. Epub 2005 Aug 1. Circulation. 2005. PMID: 16061736
• Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain.

  Onaivi ES, Ishiguro H, Gong JP, Patel S, Perchuk A, Meozzi PA, Myers L, Mora Z, Tagliaferro P, Gardner E, Brusco A, Akinshola BE, Liu QR, Hope B, Iwasaki S, Arinami T, Teasenfitz L, Uhl GR. Onaivi ES, et al. Ann N Y Acad Sci. 2006 Aug;1074:514-36. doi: 10.1196/annals.1369.052. Ann N Y Acad Sci. 2006. PMID: 17105950 Review.
• [Atherogenesis and immune inflammation].

  Nagornev VA. Nagornev VA. Biull Eksp Biol Med. 1996 Jul;122(7):4-8. Biull Eksp Biol Med. 1996. PMID: 9303696 Review. Russian. No abstract available.